DFTXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

Definium Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$32.97+0.87 (+2.71%)

Close on Oct 19, 2026

Market cap: $3.65B
P/E (TTM): –
Dividend yield: –

Definium Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	258	274	100	142	134	80	–
Short-Term Investments	154	0	–	–	–	–	–
Cash & Short-Term Investments	412	274	100	142	134	80	–
Prepaid Expenses & Other	7.73	7.88	4.17	3.91	3.68	1.43	–
Total Current Assets	419	282	104	146	137	82	–
Long-Term Investments	–	0	–	–	–	–	–
Goodwill	20	20	20	20	20	0	–
Intangible Assets	–	0	0.53	3.69	6.87	–	–
Other Long-Term Assets	0.86	0.61	0.22	0.33	–	–	–
Total Assets	440	302	125	170	164	82	–
Accounts Payable	5.35	2.01	4.14	2.11	4.18	2.02	–
Accrued Expenses	20	13	12	5.88	6.23	0.99	–
Total Current Liabilities	67	39	32	18	10	3.01	–
Long-Term Debt	41	22	14	–	–	–	–
Other Long-Term Liabilities	0.50	–	0.03	1.18	1.93	–	–
Total Liabilities	108	61	46	19	12	5.65	–
Total Debt	41	22	14	–	–	–	–
Common Stock	–	0	0	–	–	–	–
Additional Paid-In Capital	914	640	368	345	288	120	–
Retained Earnings	-583	-399	-290	-194	-138	-45	–
Comprehensive Income & Other	1.09	0.82	0.34	0.63	1.05	0.28	–
Shareholders' Equity	332	241	78	151	152	76	4.78
Total Equity	332	241	78	151	152	76	4.78
Total Liabilities & Equity	440	302	125	170	164	82	–
Shares Outstanding(shares)	99	75	41	38	28	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -64.1%

Financial strength

Current ratio: 6.95
Debt to equity: 0.04
Debt to assets: 3.3%
Cash to current liabilities: 416.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.97
Dividend yield: –